462093-57-8

Basic information

• Product Name: 2-Propenoic acid, 3,3-bis[3-(trifluoromethyl)phenyl]-, ethyl ester
• CAS NO: 462093-57-8
• Molecular Formula: C19H14F6O2
• Molecular Weight: 388.309
• Mol File: 462093-57-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-Propenoic acid, 3,3-bis[3-(trifluoromethyl)phenyl]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propenoic acid, 3,3-bis[3-(trifluoromethyl)phenyl]-, ethyl ester(462093-57-8)
• EPA Substance Registry System: 2-Propenoic acid, 3,3-bis[3-(trifluoromethyl)phenyl]-, ethyl ester(462093-57-8)

Safety Data

• Hazardous Substances Data: 462093-57-8(Hazardous Substances Data)

Upstream product

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 1868-00-4 3,3'-bis(trifluoromethyl)benzophenone 

Downstream Products

• 462093-61-4 3,3-bis[3-(trifluoromethyl)phenyl]prop-2-en-1-ol 
• 462093-65-8 3,3-bis[3-(trifluoromethyl)phenyl]prop-2-enyl chloride 

Relevant articles and documents

N-3(9)-arylpropenyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes as μ-opioid receptor agonists. Effects on μ-affinity of arylalkenyl chain modifications

Two series of N-3-arylpropenyl-N-9-propionyl-3,9-diazabicyclo[3.3.1]nonanes (1b-j) and of the reverted N-3-propionyl-N-9-arylpropenyl isomers (2b-j) as analogues of the previously reported analgesic N-3(9)-cinnamyl-N-9(3)-propionyl-3,9-diazabicyclo[3.3.1]nonanes (DBN) (1a, 2a) were synthesised and their affinity and selectivity towards opioid μ-, δ- and κ-receptors were evaluated. Several compounds (1e,i,j-2d,e,f,g,j) exhibited a μ-affinity in the low nanomolar range with moderate or negligible affinity towards δ- and κ-receptors. The representative term N-9-(3,3-diphenylprop-2-enyl)-N-3-propionyl-DBN (2d) displayed in vivo (mouse) a potent analgesic effect (ED50 3.88 mg/kg ip) which favourably compared with that of morphine (ED50 5 mg/kg ip). In addition, 2d produced in mice tolerance after a period twice as long with morphine.

NOVEL COMPOUNDS, THEIR PREPARATION AND USE

Novel compounds of the general formula (I), the use of these compounds as pharma-ceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be